Back to the main directory
Company First Look / Equity
- First Look - æ²³åˆæ¥½å™¨è£½ä½œæ‰€ (7952 JP) (Buy) - æ–°ä¸è¨ˆã®åˆ©ç›Šç›®æ¨™ã¯ä¿å®ˆçš„ãªå°è±¡ by Nomura Research
- First Look - Kawai Musical Instruments Manufacturing (7952 JP) (Buy) - New medium-term plan targets look cautious by Nomura Research
- アドビ(Buy)Adobe Summitåˆæ—¥ã®å ±å‘Š by Nomura Instinet Research
- First Look - LINE (3938 JP) (Buy) - Strategic alliance between LINE Pay and Merpay (ADR:LN US) by Nomura Research
- Quick Note - China Life Insurance (2628 HK, Neutral) - FY18 overall largely in line by Nomura Research
- Quick Note - China Resources Gas Group (1193 HK, Buy) - Takeaways from HK NDR by Nomura Research
- First Look - æ±æµ·æ—…å®¢é‰„é“ (9022 JP) (Neutral) - è¨å‚™æŠ•è³‡ã¯é«˜æ°´æº–ã€GWã®æ–°å¹¹ç·šã¯ãƒªã‚¹ã‚¯ã‚ã‚Š by Nomura Research
- Quick Note - Singapore Technologies Engineering (STE SP, Buy) - STE to acquire European satcom player by Nomura Research
- First Look - Shionogi (4507 JP) (Buy) - Nikkei: Xofluza-resistant virus discovered by Nomura Research
- Quick Note - IHH Healthcare Bhd (IHH MK, Buy) - Concerns over Turkish Lira resurface by Nomura Research
- Quick Note - Gamuda (GAM MK, Buy) - Taiwan contract shows overseas opportunities by Nomura Research
- Quick Note: Sarepta Therapeutics, Inc. (SRPT US, Buy) - Casimersen Skips Ahead Positive Data NDA ’19 by Nomura Instinet Research
- Quick Note - China Re (1508 HK, Neutral) - FY18 overall in line by Nomura Research
- First Look - アステラス製薬 (4503 JP) (Buy) - enfortumab vedotinã®P2試験æˆåŠŸç™ºè¡¨ by Nomura Research
- First Look - Astellas Pharma (4503 JP) (Buy) - Positive results from P2 trial of enfortumab vedotin by Nomura Research
- Quick Note - E-MART (139480 KS, Neutral) - Company visit takeaways by Nomura Research
- First Look - MTG (7806 JP) (Buy) - 19.9期会社予想ãŒå¤§å¹…ä¸‹æ–¹ä¿®æ£ by Nomura Research
- ä¸å›½äººå¯¿ä¿é™ºï¼ˆãƒãƒ£ã‚¤ãƒŠãƒ»ãƒ©ã‚¤ãƒ•ï¼‰(Neutral)18.12期決算：全体ã¨ã—ã¦äºˆæƒ³ç·š by Nomura Research
- First Look - Nichii Gakkan (9792 JP) (Neutral) - Announcement of additional Coco Juku closures by Nomura Research
- Quick Note - China Taiping (966 HK, Buy) - Strong execution to deliver solid growth by Nomura Research
- Quick Note - Apollo Tyres (APTY IN, Buy) - R&D centre visit takeaways by Nomura Research
- First Look - 大林組 (1802 JP) (Buy) - æ±äº¬å¤–ç’°é“ã®ç¾å ´è¦‹å¦ä¼šå ±å‘Š by Nomura Research
- First Look - LINE (3938 JP) (Buy) - LINE PayãŒãƒ¡ãƒ«ãƒšã‚¤ã¨æˆ¦ç•¥çš„æ¥å‹™ææºã‚’発表 (ADR:LN US) by Nomura Research
- First Look - Obayashi (1802 JP) (Buy) - Tokyo-Gaikan Expressway site visit by Nomura Research
- Quick Note - ENN Energy Holdings (2688 HK, Buy) - Hong Kong NDR takeaways by Nomura Research
- First Look - フレアス (7062 JP) (Not Rated) - æ–°è¦ä¸Šå ´ä¼æ¥ç´¹ä»‹ by Nomura Research
- Quick Note - CIMC Enric Holdings (3899 HK, Buy) - Hong Kong NDR takeaways by Nomura Research
- First Look - Central Japan Railway (9022 JP) (Neutral) - Capex high; risks for holiday shinkansen ridership by Nomura Research
- First Look - 塩野義製薬 (4507 JP) (Buy) - Xofluzaè€æ€§ã‚¦ã‚¤ãƒ«ã‚¹æ¤œå‡ºã®å ±é“ã«ã¤ã„㦠by Nomura Research
- Hotaru Signal - AIRTAC (1590 TT, Buy) - Hotaru alert by Nomura Research
- Quick Note - Luxshare Precision (002475 CH, Buy) - 1Q19F earnings guidance better than expected by Nomura Research
- Quick Note - Infosys (INFO IN, Neutral) - INFO acquires a subsidiary of ABN AMRO by Nomura Research
- Quick Note - China Communications Services (552 HK, Buy) - FY18: accelerated non-telco revenue growth by Nomura Research
- Quick Note - Cebu Pacific (CEB PM, Buy) - FY18 results review and analysts’ briefing by Nomura Research
- First Look - 第一三共 (4568 JP) (Neutral) - DS-8201å…±åŒé–‹ç™ºãƒ»å•†æ¥åŒ–å¥‘ç´„ç· çµã«ã¤ã„㦠by Nomura Research
- First Look - Daiichi Sankyo (4568 JP) (Neutral) - Joint development, commercialization of DS-8201 by Nomura Research
- First Look - ニãƒã‚¤å¦é¤¨ (9792 JP) (Neutral) - COCO塾ã®è¿½åŠ 閉鎖を発表　é¸æŠžã¨é›†ä¸ã¸ by Nomura Research
- Quick Note - Zhen Ding Technology Holding (4958 TT, Buy) - 4Q18 results beat on solid GM & lower opex by Nomura Research
- Quick Note - Unimicron Technology (3037 TT, Buy) - 4Q18 GM beat, thanks to strong IC substrate by Nomura Research
- First Look - MTG (7806 JP) (Buy) - Management slashes 19/9 guidance by Nomura Research
- Quick Note - Sino Biopharm (1177 HK, Reduce) - 2018 adjusted NP miss by 12% by Nomura Research